Showing 261-270 of 1310 results for "".
- Simulated Patient Encounter Part of Summer AAD Programhttps://practicaldermatology.com/news/simulated-patient-encounter-part-of-summer-aad-program/2458888/Simulated patient encounters have come to the American Academy of Dermatology's summer meeting, offering a unique, hands-on educational experience for attendees. Speaking to Seemal Desai, MD for DermTube.com's coverage of the 2015 Summer Meeting of the AAD in New York City, Kanade Shinkai
- Murad Partners with AAD to Launch Shade America Programhttps://practicaldermatology.com/news/murad-partners-with-aad-to-launch-shade-america-program/2458951/Murad, Inc. partnered with the American Academy of Dermatology (AAD) to launch Shade America, a new program that will build shade structures in parks and playgrounds across America to provide shade from the sun’s harmful rays. Through the Shade America program, Murad’s goal is to prov
- Dr. Reddy's and its Subsidiary Promius Pharma File Three NDAshttps://practicaldermatology.com/news/dr-reddys-and-its-subsidiary-promius-pharma-announce-filing-of-three-ndas/2458971/Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, LLC filed three 505(b)(2) New Drug Applications (NDAs) with the FDA. The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in
- Almirall Announces New Sustainability Strategyhttps://practicaldermatology.com/news/almirall-announces-new-sustainability-strategy/2467252/The five pillars of Planet, People, Patients, Partners, and Principles are at the center of Almirall S.A.’s new sustainability strategy, Act4Impact 2030, the company announced. The updated strategy aims at transforming the company’s sustainability roadmap and consists of 20 strategic lines
- AI In Action: Almirall, Absci AI Drug Discovery Partner to Rapidly Develop New treatments for Skin Diseaseshttps://practicaldermatology.com/news/ai-in-action-almirall-absci-ai-drug-discovery-partner-to-rapidly-develop-new-treatments-for-skin-diseases/2462135/Almirall S.A. and Absci Corporation, a generative artificial intelligence (AI) drug creation company, are teaming up to develop and commercialize AI-designed therapeutics to treat dermatological diseases. The partnership combines Absci’s Integrated Drug C
- Almirall Seeks Proposals to Better Understand Key Pathological Mechanisms of Skin Diseaseshttps://practicaldermatology.com/news/almirall-seeks-proposals-to-better-understand-key-pathological-mechanisms-of-skin-diseases/2462090/Almirall S.A. is calling for proposals to better understand key pathological mechanisms of several skin diseases through AlmirallShare, its open innovation platform. Almirall’s objective through this call is to identify and explore, through collaboration w
- Hyphens Pharma Licenses Winlevi for 10 ASEAN Countries from Cosmo Pharmaceuticalshttps://practicaldermatology.com/news/hyphens-pharma-licenses-winlevi-for-10-asean-countries-from-cosmo-pharmaceuticals/2461475/Hyphens Pharma International Limited’s subsidiary Hyphens Pharma Pte. Ltd. has entered into exclusive license and supply agreements with Cassiopea S.p.A to develop and commercialize Winlevi (clascoterone) cream 1% and all future product extensions and/or improvemenst in the treat
- Happify Health, Almirall Go Live with Digital Solution to Support Psoriasis Patientshttps://practicaldermatology.com/news/happify-health-almirall-go-live-with-digital-solution-to-support-psoriasis-patients/2461234/Happify Health and Almirall S.A.’s new digital platform Claro is live and now available to people with psoriasis in Spain, Italy and the United Kingdom. Claro was built to improve the mental well-being of people with psoriasis through cognitive behavioral therapy, positive psychology, and m
- Almirall Finalizes Acquisition of Allergan US Medical Dermatology Portfoliohttps://practicaldermatology.com/news/almirall-finalizes-acquisition-of-allergan-us-medical-dermatology-portfolio/2457600/Almirall, S.A. finalized its acquisition of products from Allergan's Medical Dermatology unit in the US: Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), and Cordran Tape (flurandrenolide). In addition, sarecycline, a New Chemical Entity (NCE) currently under FDA review for appr
- Patent Challenge Filed for Generic Version Of Soolantra Creamhttps://practicaldermatology.com/news/patent-challenge-filed-for-generic-version-of-soolantra-cream/2458120/Perrigo Company plc's subsidiary has filed a Paragraph IV Abbreviated New Drug Application with the FDA for a generic version of Soolantra® (ivermectin) cream, 1%. Following notification from Perrigo, Galderma Laboratories, L.P., Galderma S.A., and Nestle Skin Health S.A., filed a